White Paper: corporate sustainability regulations & reporting updates

The science is clear: Emissions need to fall 45% by 2030 to avoid the worst climate impacts.


Limiting global warming to well below 2 degrees Celsius can avoid further impact on global health, according to the Intergovernmental Panel on Climate Change (IPCC). Healthcare stakeholders must play their part by accelerating the delivery of patient-centric, equitable, net zero health systems.

As the latest report by the IPCC shows, this is no longer a challenge for tomorrow: we are already seeing the impacts today with increased incidence of events such as extreme heat, floods, and wildfires across the globe. We need to act urgently and reduce emissions globally to limit further global warming.

The pharmaceutical industry has a significant impact on the environment due to the large quantities of energy, water, and raw materials required for drug manufacturing.

As a result, there is growing pressure for pharmaceutical companies to embed environmental sustainability into their operations and corporate culture. By providing greater transparency and accountability on their environmental performance, life science organisations can build trust with stakeholders, enhance their reputation, and drive long-term value for their business.

As the climate crisis escalates, so does scrutiny of how companies are addressing environmental sustainability challenges, and new regulations are shaping the way global supply chains operate, promoting sustainability and environmental responsibility. 

There are several environmental reporting frameworks and standards that pharma organisations can use to report on their environmental performance, these regulations and initiatives are evolving to facilitate sustainable supply chain operations. 

Read the full report “Regulations are evolving to facilitate sustainable supply chain operations” to understand the environmental reporting frameworks and standards and prepare ahead of looming deadlines.